Revenues rise 2.4% Y/Y in FQ2 for Medtronic (MDT) — the figure rises to 3.3% stripping out currency impact.
International sales tick 3% higher and accounted for 45% of MDT's top-line for the period.
"Revenue growth was in-line with our outlook for the year," CEO Omar Ishrak says, adding that the company is "performing at or better than the market in almost every one of [its] businesses."
Revenue growth by segment (constant currency): Cardiac and Vascular, +4%; Restorative Therapies, +2%; Diabetes, +3%.
FY14 outlook: EPS guidance unchanged at $3.80-3.85 on revenue growth of 3-4%. (PR)